A high throughput assay provides novel insight into type VII secretion in

Staphylococcus aureus

Yaping Yang[1] (https://orcid.org/0000-0002-0223-0200), Aaron A. Scott[1]

(https://orcid.org/0009-0007-4577-8042), Holger Kneuper[2] (https://orcid.org/0000-0003-

0712-8317), Felicity Alcock*[1] (https://orcid.org/0000-0002-3983-6097) and Tracy Palmer*[1]

(https://orcid.org/0000-0001-9043-2592)

[1] Newcastle University Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2
4HH, UK.

[2] Present address: Folium Science, Old Market, Midland Road, Bristol BS2 0JZ

*for correspondence Felicity Alcock (felicity.alcock@newcastle.ac.uk) or Tracy Palmer

(tracy.palmer@newcastle.ac.uk)

Keywords: Type VII secretion system, *Staphylococcus aureus*, bioluminescence, NanoBit,

Toxin, accessory factors

Abstract

Successful colonisation by the opportunistic pathogen *Staphylococcus aureus* depends on its

ability to interact with other microorganisms. *S. aureus* strains harbour a T7b-subtype type

VII secretion system (T7SSb), a protein secretion system found in a wide variety of Bacillota

which functions in bacterial antagonism and virulence. Assessment of T7SSb activity in *S.*

aureus has been hampered by low secretion activity under laboratory conditions, and the lack

of a sensitive assay to measure secretion. Here we have utilised NanoLuc Binary Technology

to develop a simple assay to monitor protein secretion via detection of bioluminescence.

Fusion of the 11 amino acid NanoLuc fragment to the conserved substrate EsxA permits its

extracellular detection upon supplementation with the large NanoLuc fragment and

luciferase substrate. Following miniaturisation of the assay to 384 well format, we use high-

throughput analysis to demonstrate that T7SSb-dependent protein secretion differs across

strains and growth temperature. We further show that the same assay can be used to monitor

secretion of the surface-associated toxin substrate TspA. Using this approach we identify

three conserved accessory proteins required to mediate TspA secretion. Co-purification

experiments confirm that all three proteins form a complex with TspA.

Background

The opportunistic pathogen *Staphylococcus aureus* is a major cause of both nosocomial and community infections. It is a frequent coloniser of animals and humans and infections can result in a range of life-threatening diseases such as pneumonia, endocarditis and sepsis. It is notorious for developing resistance to frontline antimicrobials, with methicillin resistance now widespread and vancomycin resistance also increasing [1, 2]. Like many Gram-positive bacteria, *S. aureus* carries a specialised protein secretion machinery called the type VII secretion system (T7SS), which it utilises to secrete antibacterial toxins targeting competitor bacteria (reviewed in [3]). T7SS-mediated antagonism is likely to be important for colonisation [4], and the *S. aureus* T7SS has been shown to be required for virulence in mouse infection models [5-9]. There are several distinct T7SS subtypes, of which the T7SSa and T7SSb are the best characterised [10]. The T7SSb is widely distributed among Bacillota, and has been studied to date in species of *Streptococcus*, *Staphylococcus*, *Bacillus* and *Enterococcus* [8, 11-13]. However, in many cases functional and mechanistic studies have been hindered by low secretion activity in laboratory conditions.

The *S. aureus* T7SSb is encoded on the core genome at the *ess* locus, and four variant locus types have been identified, termed *essC-1 – essC-4*. The genes at the 5' end of the *ess* locus are highly conserved and encode core components of the secretion machinery, while the 3' end codes for different complements of variant-specific substrate and accessory genes [4, 14]. The primary component of the T7SSb transmembrane channel is the ATPase EssC, inferred from its homology to the EccC component of the mycobacterial T7SSa channel whose structure has been solved by cryo-electron microscopy [15, 16]. EssC has a conserved N-terminus, two transmembrane domains which likely form the secretion channel, and four C-terminal ATPase domains, the latter two of which are variant-specific and provide substrate specificity [17]. Three additional membrane proteins, EsaA, EssA and EssB, and two small globular proteins, EsxA and EsaB, are further essential components of the T7SSb secretion system [6, 8, 18].

In addition to being a core component of the T7SSb secretion system, EsxA is itself a T7SS secretion substrate. EsxA secretion is essential for the export of other T7SSb substrates, and

it appears to be co-secreted with at least some of them [8, 19]. EsxA is a member of the

WXG100 protein family, which are helical hairpin proteins that often, but not always, harbour

a central W-x-G sequence motif [20, 21]. In addition to EsxA, other WXG100-like proteins,

with more specialised functions, are also found in T7SSb+ strains. These are usually encoded

at genetic loci with genes for larger T7SSb-secreted toxins. T7SSb toxins contain an LXG

domain, which can be located either at the protein N-terminus (for example TelB, EsaD and

TspA) or C-terminus (e.g. TslA) [6, 11, 18, 22-25]. Prior to secretion, the co-encoded WXG100-

like proteins, which have been termed Laps (for LXG-associated α-helical proteins) bind to the

LXG domain of the cognate toxin partner. This interaction generates a secretion-competent

rod-shaped complex, and conserved sequence motifs on both the LXG domain and one of the

Laps constitute a T7SSb-targeting signal [23, 24, 26, 27]. In some instances, a globular protein

is also encoded at the toxin genetic locus, which also facilitates toxin secretion [24, 27].

TspA is a membrane-depolarising toxin with antibacterial activity that is encoded by all *S.*

aureus strains analysed to date. Following secretion, TspA associates with the cell surface and

can only be released experimentally by digestion of the cell wall [22]. Unlike other

characterised LXG toxins, no WXG100-like partner proteins are encoded at the *tspA* locus, and

its secretion requirements are unclear. Assessing secretion by the *S. aureus* T7SS is hampered

by low secretion activity in laboratory growth media. Moreover, the lack of cleavable signal

peptides on T7SSb substrates means there is no size difference between the exported and

cytosolic forms making cellular lysis a confounding issue, particularly where cell wall digestion

is also required. To circumvent these difficulties, we have developed a novel secretion assay

that makes use of NanoLuc binary technology [28]. We show that this is a robust reporter

system that can be used to monitor both secreted and cell-surface localised T7SSb substrates

and which is amenable to high-throughput analysis. Using this assay we identify three genes

that are required for efficient export of TspA, and demonstrate that the encoded proteins

directly interact with the toxin.

Methods

Bacterial strains, plasmids and growth conditions

E. coli was cultured in LB medium (Melford) and *S. aureus* was cultured in tryptic soy broth

(TSB; Oxoid) with chloramphenicol (10 µg/ml) where required. *E. coli* strains DH5α (*Δ(argF-*

lac)169, φ80dlacZ58(M15), ΔphoA8, glnX44(AS), deoR481, rfbC1, gyrA96(NalR), recA1,

endA1, thiE1 and hsdR17) and JM110 *rpsL thr leu thi lacY galK galT ara tonA tsx dam dcm*

glnV44 Δ(lac-proAB) e14- [F' *traD36 proAB⁺ lacI�q lacZ*ΔM15] *hsdR17*(rK⁻mK⁺) were used for

cloning and preparation of plasmids for electroporation, respectively, and M15 harbouring

pREP4 (*F-, lac, ara, gal, mtl* [*KanR, lacI*]) was used for protein overproduction. *S. aureus* strains

and plasmids used are listed in Tables 1 and 2, respectively. Chromosomal deletion of *essC*

was accomplished by allelic exchange using plasmid pIMAY [29] carrying the *essC* flanking

regions. Insertion of the pep86 tag on the chromosome of COL and COLΔ*essC* used an updated

system with plasmid pIMAY-Z [30]. pIMAY plasmids were created using standard restriction

cloning techniques, and pIMAY-Z-esxApep86 was created using HiFi assembly (NEB). Plasmids

pRab11-esxApep86 and pRab11-tspA$_{1-328}$-pep86_2603_2602_2601 for NanoLuc secretion

assays, and plasmid pQE70-$_{Tstrep}$SACOL2603$_{myc}$-2602-2601$_{HA-his}$TspA for protein purification

were created using HiFi assembly (NEB, E0554S). *SACOL2603, SACOL2602* and *SACOL2601*

were individually deleted from pRab11-tspA$_{1-328}$-pep86_2603_2602_2601 using the Q5 site-

directed mutagenesis kit (NEB). Oligonucleotides are listed in Table S1.

NanoLuc secretion assays

Furimazine was purchased from Promega (N1610) and used according to the manufacturer's

instructions. The NanoBit large subunit 11S was purified from *E. coli* BL21(DE3) [pBAD-$_{6H}$11S]

using the published protocol [28] and was used at a final concentration of 5 µM. For assay of

5 ml cultures, *S. aureus* strain COL were cultured as described above. Once cultures had

reached a density of 0.5 (OD$_{600}$), anhydrotetracycline (ATC; 250ng/ml) was added to induce

expression of EsxA-pep86. Cells were harvested at a density of 2 (OD$_{600}$) by centrifugation at

16,000 x g, 20°C. Cell pellets were resuspended in TBS + 50µg/ml lysostaphin (LSPN, Ambi)

and incubated for 10 minutes at 37°C. 100µl of each sample was supplemented with 5µM 11S

and 2µl furimazine (1:100 dilution of stock solution) in a 96-well plate (Greiner, REF655073)

with an approximate final well volume of 105µl. Luminescence at 460 nm was read 3 minutes

after incubation of the plate at room temperature, with a FLUOstar Omega using a gain value

of 3,000. Samples from the same cultures were prepared for immunoblot and analysed with

antibodies as previously described [24]. For assays in 384-well plates, overnight *S. aureus*

cultures were subcultured in fresh TSB at a density (OD_{600}) of 0.001 for assay of EsxA-pep86

secretion or 0.01 for assay of $TspA_{NT}$-pep86 secretion and cultured at 37 °C/34 °C/30 °C with

shaking at 200rpm in a 384-well plate (Greiner, REF781098), with a well volume of 50µl. In

general, for each assay one row of the 384 well plate was used (16 wells, i.e. 16 technical

replicates). This was repeated in triplicate with three separate starter cultures (i.e. three

biological replicates). The exceptions to this are in Fig. 2 D and E, where in Fig 2D, there is one

biological replicate but 64 technical replicates and Fig 2E where there are three biological

repeats each of 64 technical replicates. For COL strains grown at 37 °C, 250 ng/ml ATC was

added after 320 min and 11S and furimazine were added after 380 min. For all other strains

500 ng/ml ATC was added after 180 minutes (37°C cultures), 220 minutes (34°C cultures), or

240 minutes (30°C cultures). 11S and furimazine were added at 220 minutes (37°C cultures),

280 minutes (34°C cultures) or 300 minutes (30°C cultures). OD_{600} and luminescence readings

were taken every 10 minutes. To measure total luminescence (i.e. combined extracellular and

cytoplasmic levels), 50µg/ml lysostaphin in TBS was added to each well and incubated for 10

minutes at 37°C. luminescence readings were taken after supplementation of 11S and

furimazine.

Cell fractionation and western blot

Single colonies of *S. aureus* harbouring the appropriate pRab11-based plasmid were cultured

in TSB medium with chloramphenicol. The following day, 600 µl of overnight culture was sub-

cultured into 10 ml of fresh TSB. When the culture reached OD_{600nm} = 0.5-0.6, 500 ng/ml of

ATC was added to induce plasmid-encoded gene expression. Cells were harvested at OD_{600} =

2. A 1.8 ml aliquot of the culture supernatant was retained, filtered through a 0.22µM sterile

filter and the filtrate supplemented with 50 µg/ml sodium deoxycholate (Merck, 89904) and

10% TCA (Cambridge Bioscience, 700016-10 ml-CAY). Proteins were precipitated on ice

overnight and subsequently pelleted by centrifugation. After washing with 80% ice-cold

ethanol, the pellet was resuspended in resuspension buffer (50mM Tris-HCl, pH 8.0, 4% SDS,

10% glycerol) then boiled with 1/3 volume of 4x Laemmli sample buffer (Bio-Rad, 1610747)

for 10 mins. This was taken as the supernatant fraction. The harvested cells were resuspended in Tris-buffered saline containing 100 μg/ml lysostaphin and incubated at 37 °C for 30 mins. This was then supplemented with 1/3 volume of 4x Laemmli sample buffer and boiled for 10 min. This was taken as the whole cell fraction.

For Western blot analysis, samples were separated by SDS PAGE, transferred to nitrocellulose membrane using a Trans-Blot (Bio-Rad) with Whatman paper soaked in transfer buffer composed of 25 mM Tris, 192 mM glycine pH 8.3, 10% methanol, and analysed by incubation with one of the following primary antibodies: anti-EsxA [8], anti-TrxA [31], anti-HA tag (Merck, H9658), anti-strep tag (Qiagen, 34850), anti-6*his tag (Thermo Fisher Scientific,11533923), anti-myc tag (Abcam, Ab23), and an HRP-linked secondary antibody. A goat anti-mouse antibody (Bio-Rad, 1706516) was used with primary antibodies against the strep, myc and HA tags. A goat anti-rabbit antibody (Bio-Rad, 1721019) was used with all other primary antibodies. All uncropped western blots are provided in the supplementary materials.

Protein purification

LB medium containing ampicillin (0.125 mg/ml) was inoculated 1/100 with an overnight preculture of strain M15 strain carrying pQE70-$_{Tstrep}$SACOL2603-$_{myc}$2602-2601$_{HA}$-$_{his}$TspA and grown at 37°C for 2 to 3 h with aeration, until OD$_{600}$ reached ~0.5. Cultures were then supplemented with 0.5 mM isopropyl β-d-1-thiogalactopyranoside (IPTG), and grown at 18°C overnight, then harvested by centrifugation. Cell pellets were resuspended in binding buffer W (100 mM Tris/HCl, pH 8.0, 150 mM NaCl, and 1 mM EDTA). Cells were lysed by sonication, the resulting cell lysate was clarified by centrifugation at 20,000 g for 30 min, and the supernatant was applied to a 1ml Strep-tactin XT column (IBA, 2-4021-001), washed with bugger W (100 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA) and the bound proteins were eluted in buffer BXT (IBA, 2-1042-025). Proteins eluted from the Strep-tactin XT column were concentrated using a 50 MWCO Vivaspin centrifugal concentrator (Global Life Sciences Solutions Operations, 28932318) before injection onto a Superdex S200 10/300 GL column (Cytiva) equilibrated in 50 mM HEPES pH 7.5, 150 mM NaCl. Samples were analysed by SDS PAGE using Mini-PROTEAN® TGX™ Precast Gels (Bio-Rad).

Other methods

Secretion data were analysed and presented using Prism (Graphad). Raw data is available for

download from FigShare (https://doi.org/10.6084/m9.figshare.25368598). Gene

neighbourhood digrammes were generated using clinker (https://cagecat.bioinformatics.nl;

[32]).

Results

A NanoLuc assay for measuring Type VII-dependent secretion in Staphylococcus aureus

Previous methods to monitor *S. aureus* T7SSb secretion activity have relied almost exclusively

on western blotting. Assessing secretion of endogenous WXG100-family proteins, in

particular EsxA, involves isolating and concentrating culture supernatants, usually by

precipitation with trichloroacetic acid [6, 8, 19, 33]. Furthermore, detection of natively

produced LXG toxins is generally too low to detect by western blotting even from

concentrated supernatant samples, and assessing their secretion has required

overproduction of epitope-tagged variants from an inducible plasmid [22-25]. These methods

depend on the availability of good quality antibodies, are often poorly reproducible, and are

difficult to quantify.

To circumvent these issues we utilised NanoLuc binary technology (abbreviated to NanoBit)

to develop a new assay to monitor T7 secretion. NanoLuc is an engineered variant of a deep

sea shrimp luciferase protein. It is relatively small (19 kDa) and has superior biophysical

characteristics compared to other luciferases [34]. NanoBit is a complementation reporter

system which has previously been used to investigate protein secretion via the Sec and Tat

translocons in *E. coli* [28, 35, 36]. Two separate NanoLuc subunits (11S, a 156 amino acid large

subunit and pep86, an 11 amino acid small subunit) combine with high affinity to generate

the functional enzyme, which luminesces with high intensity at 460 nm in the presence of the

substrate furimazine and molecular oxygen [34].

We first selected EsxA as our model substrate (Fig 1A). EsxA is produced at significantly higher

copy than other T7SS components [8] and can be detected by Western blot in culture

supernatants of the *essC-1* strain COL relatively reliably, allowing us to correlate our new

assay with data from traditional immunoblot assays. We constructed plasmid pRab11-

esxApep86 which permits inducible overproduction of EsxA with the NanoBit small subunit,

pep86, fused to its C-terminus. This plasmid was transferred into wild-type and Δ*essC* variants

of COL, and the wild-type strain was also transformed with empty pRab11 as a further control.

Cultures (5ml volume in 50ml falcon tubes) were supplemented with anhydrotetracycline

(ATC) and grown at 37°C to mid logarithmic phase ($OD_{600} \cong 2.0$). At this point samples of

whole cell culture, culture supernatant and lysostaphin-lysed cells were prepared. The

NanoBit large subunit, 11S, and the NanoLuc substrate furimazine were added to serial two-

fold dilutions of these samples, and luminescence readings were taken (Fig. 1B). Cell lysate

and culture supernatant samples from the same cultures were also analysed by immunoblot

(Fig. 1C).

Luminescence was detected in all samples except those from cells carrying empty vector,

signifying an EsxA-pep86–specific luminescence signal (Fig. 1B). Similar luminescence

readings were obtained for both the whole cell culture and the supernatant samples,

demonstrating that external pep86 can be measured without centrifugal separation of culture

supernatants (Fig. 1B). Deletion of *essC* resulted in a dramatic reduction in the level of

extracellular EsxA-pep86 compared to the wild-type strain, while the cytoplasmic level was

similar in both strains. This confirms that the extracellular EsxA-pep86-dependent

luminescence signal is due to secretion by the T7SS. We assign that residual low level of

extracellular EsxA-pep86 in the *essC* mutant strain to cell leakage/lysis.

When fractions of the same cultures were analysed by immunoblot a single band at ~11 kDa

was detected with antibodies against EsxA in all three strains (Fig. 1C), regardless of whether

the cells harboured pRab11 or pRab11-esxApep86. Since two of the three strains analysed

produce both endogenous chromosomally-encoded EsxA (11 kDa) and plasmid-encoded

EsxA-pep86 (12.3 kDa), we infer that this 11 kDa band corresponds to endogenous EsxA, and

that the pep86 fusion inhibits detection by the EsxA antibodies (see also Fig. 2C where

chromosomal tagging of *esxA* with pep86 inhibits antibody detection).

As an additional control, we constructed a similar fusion of a cytoplasmic protein, TrxA with

an N-terminal pep86 tag (pRab11-pep86-TrxA) and assayed this in the same way.

Luminescence readings showed that while pep86-TrxA was produced, barely any signal was

detected outside the cells (Fig. 1D). Immunoblots confirmed the cytoplasmic localisation of

TrxA and showed that EsxA was secreted normally in these strains, although similarly to EsxA-

pep86, the pep86-TrxA fusion was not detected by our TrxA antibodies (Fig. 1E). In summary,

Figure 1 demonstrates that luminescence readings correlate with T7-dependent secretion of

EsxA-pep86, and that extracellular EsxA-pep86 can be measured in unprocessed whole cell

cultures.

High throughput analysis of EsxA secretion

Having established that we can use the NanoBit assay to measure T7SS secretion in *S. aureus*,

and that we can directly detect extracellular EsxA-pep86 from growing cultures, we next

sought to miniaturise it for high throughput format to improve quantitation and sensitivity.

To this end we engineered a C-terminal pep86 fusion onto chromosomally-encoded EsxA, to

avoid the need for an inducible plasmid. This ensures the assay is undertaken using a system

that is as close to native as possible. To assess whether the chromosomally-encoded EsxA-

pep86 fusion was competent to support T7 secretion, we transformed this strain with a

plasmid encoding a HA-tagged copy of the T7 LXG toxin substrate EsaD alongside its accessory

proteins. Immunoblot data for cell lysate and culture supernatant samples (Fig. 2A) showed

that although the EsxA-pep86 fusion was not detected by our antibodies, as we had seen

previously with the plasmid-encoded fusion, secretion of EsaD-HA was unaffected by the

presence of the pep86 tag on EsxA. We conclude that EsxA-pep86 is functional (Fig. 2A).

We next performed growth curves for 50 µl cultures of COL*esxApep86* and an otherwise isogenic

essC mutant in 384-well plate format. Strains grew slowly under these conditions, with

cultures reaching stationary phase approximately 20 hours (1200 minutes) after inoculation

at an OD_{600} of 0.001 (Fig. 2B). The *essC* mutant strain grew slightly more slowly in exponential

phase but reached the same final OD_{600} as the *essC*$^+$ strain. The half-life of the NanoLuc

luminescence signal is reported to be approximately 120 minutes (Promega) meaning that

continuous monitoring of secreted EsxA-pep86 throughout exponential growth would not be

possible. We therefore chose to monitor secretion during early exponential phase, and to this

end furimazine and 11S were added to cultures at the beginning of exponential phase, after

six hours (360 minutes) growth (Fig. 2B, dotted line) to initiate luminescence. Luminescence

readings were then taken at ten minute intervals. The luminescence signal for COL*esxApep86*

cultures initially rose, peaking 70 minutes after initiation of luminescence, indicating that cells

were actively secreting protein during this time (Fig. 2C). The subsequent decline in

luminescence intensity is likely due to signal decay, although degradation of pep86 might also

contribute. As seen in the previous assay shown in Figure 1, some leakage of EsxA-pep86

occurred in the Δ*essC* strain (Fig. 2C).

To analyse the distribution of secretion activity within a clonal population, a single colony of

each of COL*esxApep86* and COLΔ*essCesxApep86* was used to inoculate overnight cultures, and these

were each used to inoculate 64 x 50 µl cultures and assayed as described above.

Luminescence readings taken at 430 minutes (OD_{600} = 0.23) were used to generate a scatter

plot of individual data points (Fig. 2D). This analysis reveals a moderate distribution of

secretion activity in replicate cultures of COL*esxApep86*, however the distribution of extracellular

EsxA-pep86 levels in the control COLΔ*essCesxApep86* strain was quite broad, overlapping the

essC⁺ strain and highlighting the requirement for a high throughput assay. The same analysis

was repeated for three independent cultures of each strain and this did not increase

variability (Fig. 2E).

Variable secretion characteristics of different* S. aureus *strains

It has previously been reported that T7SS activity varies across different *S. aureus* isolates and

growth conditions [8, 19, 33]. However direct comparison across different *S. aureus* strains

has been hampered by low secretion activity (often below the detection limit) and low

reproducibility (our unpublished observations). We therefore used the NanoBit assay to

compare secretion across cell cultures of five additional *S. aureus* isolates, two of which (like

COL) carry the *essC-1* variant *ess* locus (RN6390 and JP5347), and one representative isolate

for each of *essC-2* (10.125.2X), *essC-3* (MRSA252) and *essC-4* (EMRSA15). Each strain, along

with its otherwise isogenic Δ*essC* mutant, was transformed with pRab11-esxApep86 and

assayed for EsxA-pep86 secretion in 384-well plates. Growth curves showed that each Δ*essC*

strain grew similarly to its parental strain (Fig. S1A). The five additional strains tested here all

entered exponential phase faster than COL, and so the timing of addition of ATC (to induce

EsxA-pep86 production) and of 11S and furimazine was adjusted accordingly (see methods).

T7SS-dependent secretion of EsxA-pep86 was observed, but to varying degree, in the three

essC-1 isolates and the *essC-2* strain 10.1252.X. However no T7-secreted EsxA could be

detected in the *essC-3* (MRSA252) and *essC-4* (EMRSA-15) strains (Fig. 3A, S1B). To confirm

that EsxA-pep86 was being produced in all of the strains we measured total luminescence in

each culture following in-well cellular lysis (a combined measure of cytoplasmic and secreted

EsxA-pep86 levels (Fig. S1C). Substantive luminescence could be detected even in lysed

cultures of MRSA252 and EMRSA-15, indicating that these strains produce but do not secrete

EsxA-pep86.

Since no T7SS activity was detected for strains MRSA252 and EMRSA15 grown at 37°C we

wondered whether these isolates might exhibit a different temperature dependence for

secretion. We therefore repeated the NanoBit assay with these strains, alongside RN6390 as

an *essC-1* control, using cell cultures growing at 30°C and 34°C (Fig. 3B and S2). For EMRSA15,

EsxA-pep86 was secreted at both of the lower temperatures, while for MRSA252 the lower

temperatures made little difference to secretion activity, which was negligible at all

temperatures tested. EsxA was secreted similarly at all three temperatures in RN6390 (Fig. 3B

and S2). Temperature therefore contributes to the regulation of T7SS activity in *S. aureus* in a

strain-specific manner. Of note, EsxA-pep86 leakage was markedly lower at 30°C and 34°C

than at 37°C in each of the Δ*essC* strains (Fig. S2B).

Identification of TspA secretion partners

TspA is a membrane-depolarising LXG toxin found across all *S. aureus essC* variant strains. It

is encoded at a locus remote from the T7SS structural genes and precedes a string of non-

identical genes coding for DUF443 membrane proteins which provide protection against TspA

activity [22] (Fig. 4A). Recent analysis of other T7SSb LXG toxins has revealed a common

mechanistic feature for secretion, involving formation of a hetero-oligomeric pre-secretion

complex between the LXG domain and helical hairpin partner proteins encoded at the same

genetic locus as the toxin [24, 26, 27, 37]. Logically, the TspA LXG domain should also be

expected to require similar helical binding partners to generate a secretion-competent

structure. However, there are no candidate genes coding for predicted helical proteins in the

immediate neighbourhood of *tspA* (*SACOL0643*) (Fig. 4A).

Genomic analysis previously identified a conserved module of three small genes, potentially

implicated in T7 secretion, at a locus distant from both the *tspA* and *ess* gene clusters [4] (Fig.

4A, shaded orange, yellow and blue). In a handful of *S. aureus* strains, for example SID53, a

second homologue of *tspA* is present at this locus, along with a DUF443-encoding immunity

gene (Fig. 4A). However, in most well-studied strains, including COL, USA300 and RN6390

there is no *tspA* homologue or immunity gene at this locus, although the small genes are

always present. This raised the possibility that the conserved cluster may be required for the

biogenesis of TspA. Analysis of the encoded proteins indicates that SACOL2603 and

SACOL2602 are predicted to be helical hairpin proteins belonging to the Lap1 (DUF3130) and

Lap2 (DUF3958) families of WXG100-like export factors, respectively. Members of these

protein families have been characterised in *Streptococcus intermedius* and shown to interact

with the LXG domain of the lipid II phosphatase toxin, TelC [11, 26]. Following the

nomenclature developed in *S. intermedius* and based on results described below we have

renamed SACOL2603 and SACOL2602 LapT1 and LapT2, respectively (for LXG-associated

alpha helical protein for TspA). The third protein encoded at this locus, SACOL2601, has a

DUF4176 domain. Genes encoding DUF4176 domains are frequently associated with T7SS loci

[3] and the involvement of a DUF4176 domain-protein in LXG toxin secretion was recently

determined in *S. intermedius* [27].

We therefore adapted the NanoBit assay to test the prediction that LapT1, LapT2 and

SACOL2601 function in TspA secretion. We constructed a plasmid carrying $tspA_{1-328}$-*pep86*,

SACOL2603/lapT1, SACOL2602/lapT2 and *SACOL2601*, avoiding issues arising from TspA

toxicity by using a truncated version lacking the toxin domain but supplied with a C-terminal

pep86 tag. Due to the slow growth kinetics of strain COL in 384-well plates we carried out

assays in RN6390, whose sequence is identical to that of COL at the *tspA* and *SACOL2603* loci,

except for a single (synonymous) nucleotide change in *tspA*. Following our observation of

much lower EsxA-pep86 leakage into the supernatant at lower temperatures, we opted to

conduct the secretion assays at 34°C.

After introduction of the plasmid into RN6390 wild-type and Δ*essC* strains, we measured

luminescence in whole cell cultures, and in clarified culture supernatant following pelleting of

cells (Fig. 4B). The presence of pep86-tagged $TspA_{NT}$ in whole cell cultures was clearly

detected, dependent on an active T7SS. However little or no $TspA_{NT}$ was detected in the

fractionated culture supernatant, confirming the previous finding that TspA is cell surface-

associated rather than fully secreted [22]. These results also indicate that the TspA toxin

domain (residues 329-469) is dispensable for cell surface attachment.

To determine whether any of LapT1, LapT2 and SACOL2601 are required to support secretion

of TspA, we individually deleted each of the encoding genes from the plasmid and used the

high throughput assay in whole cell cultures to assess export of pep86-tagged $TspA_{NT}$. Fig. 4C

indicates that in the absence of each gene, significantly less $TspA_{NT}$-pep86 could be detected

in whole cell cultures, while the cytoplasmic levels (deduced from measuring total

luminescence per well following lysis) were not much affected (Fig S3B). We conclude that

each of LapT1, LapT2 and SACOL2601 support TspA secretion. It should be noted the

chromosomal copy of the *SACOL2601-2603* gene cluster is present in these strains and may

account for some of the residual secretion seen from the plasmid deletion constructs.

Previous work has reported that LXG proteins form a stable pre-secretion complex with their

cognate helical hairpin secretion partners [23, 24, 26, 27]. To investigate whether any of

LapT1, LapT2 or SACOL2601 interact with TspA, we co-produced all four proteins in *E. coli*.

The recombinant proteins carried an N-terminal twinstrep tag on LapT1 for purification, and

a C-terminal HA, N-terminal myc and N-terminal his tag on SACOL2601, LapT2 and TspA,

respectively, for detection. Complexes were purified by streptactin affinity chromatography

and analysed by size exclusion chromatography (SEC; Fig. 4D) and both SDS PAGE and western

blotting (Fig. 4E). All four proteins co-eluted in the SEC main peak confirming that they exist

as a tetrameric complex. Taken together our results indicate that the *SACOL2601-2603* gene

cluster is required for the biogenesis of TspA.

Discussion

Here we report a novel, sensitive assay for monitoring protein secretion by the T7SS in *S. aureus*, using the NanoBit split luciferase system. The 11 amino acid pep86 fragment of NanoLuc is small enough to be compatible with secretion when fused to the WXG100 protein EsxA, or to a larger LXG protein substrate. As the presence of luminescence from secreted proteins can be measured directly in unprocessed cell cultures, this enables high throughput screening of large numbers of strains and growth conditions.

Most studies of the *S. aureus* T7SS to date have focussed on secretion by *essC-1* strains, using a handful of isolates. Strains exhibit high genetic diversity at their T7 loci [14], but experimental investigation of *essC-2 - essC-4* variant strains has previously been constrained by low activity in lab conditions, and the lack of a sensitive secretion assay [33]. Using the NanoBit assay we found substantial variability in the secretion efficiencies of such strains, and their temperature dependence. In particular, the EMRSA15 T7SS (an *essC-4* variant strain), which was inactive at 37°C, exhibited a significant level of secretion at 30°C and 34°C suggesting a role for temperature in T7SSb regulation. Interestingly, *ess* transcription and T7 secretion were previously shown to be activated by reducing membrane fluidity, which was achieved by treating cells with *cis*-unsaturated fatty acids [38, 39]. Temperature-induced changes in membrane fluidity may potentially account for the differences in secretion observed here.

A number of pathways have been implicated in transcriptional regulation of the *S. aureus* T7SS, including the SaeRS and ArlRS two-component systems, the Agr quorum-sensing system and the alternative sigma factor SigB [19, 38, 40-43]. However, the complex regulatory picture is far from complete and key questions around how, why and when the secretion system is expressed remain unanswered. Moreover, additional factors may activate secretion at the post transcriptional level, for example the presence of haemin has been linked to post-transcriptional activation of the T7SS in some strains [33, 44]. The availability of a high throughput assay will facilitate screening of a range of conditions, paving the way for a much more detailed analysis of T7 regulation than has been possible to date.

We employed the NanoBit assay to explore the secretion of the surface-attached LXG toxin,

TspA. While other LXG toxins characterised to date are encoded alongside accessory proteins

essential for their biogenesis [24, 26, 27], secretion partners for TspA had not been identified.

A conserved cluster of three genes remote from the *tspA* locus had previously been

bioinformatically linked to the T7SS [4]. We showed that each of these genes supports

secretion of a TspA-pep86-fusion suggesting that their genomic conservation is because they

are required for TspA biogenesis. This conclusion was further supported by co-purification

experiments, where tagged variants of the three proteins formed a complex with TspA. Two

of these genes, *SACOL2603* and *SACOL2602* code for helical hairpin proteins of the DUF3130

and DUF3958 families, respectively. The LXG toxins, TelC and TelD, from *S. intermedius* both

require proteins from each of these families for secretion, with Lap1, being a DUF3130 protein

and Lap2 a DUF3958. In each case the Lap1 and Lap2 proteins were shown to interact with

the LXG domain of their cognate toxin partners. In keeping with this nomenclature, we have

renamed SACOL2603 as LapT1 and SACOL2602 as LapT2. Klein *et al*. [26] identified a

conserved FxxxD motif close to the C-terminus of LapD1, showing that individual alanine

substitutions of either conserved residue was sufficient to prevent TelD secretion. LapD1 and

LapT1 share only limited sequence similarity (Fig. S4) however an FxxxD motif is present at

the same position in both proteins. This motif is conserved across LapT1 homologues in other

staphylococci and in enterococci. It remains to be determined whether this serves as a

secretion motif for TspA export.

The third protein gene, *SACOL2601*, codes for a DUF4176 protein. Interestingly, proteins of

this family are also encoded in the *S. intermedius telA*, *telB* and *telD* gene clusters, but not

telC. While the homologue encoded at the *telA* locus was shown to be essential for TelA

secretion, it was not required for TelC export [27]. It is not clear whether TelC requires a

DUF4176 protein encoded by a different cluster, or whether its secretion occurs

independently of such a protein. In addition to TspA, a variant-specific LXG protein coding

gene is found at the *ess* loci of *essC-1*, essC-*2*, *essC-3* and *essC-4 S. aureus* strains [4]. However,

no DUF4176-encoding genes are found at any *ess* loci, suggesting either they are not

universally required, or that a single DUF4176 protein might function in secretion of multiple

substrates. Further work would be required to investigate this.

In conclusion we describe a novel, sensitive assay to assess secretion of T7 substrate proteins

in *S. aureus*. We anticipate this approach should be broadly applicable for the study of type

VII secretion across a range of organisms.

Acknowledgements

This study was supported by Wellcome Trust Investigator awards 10183/Z/15/Z and 224151/Z/21/Z to TP, a China Scholarship Council PhD studentship to YY and a Newcastle University research scholarship to AAS. We thank Ben Berks and Xiaolong Liu for advice and reagents for the NanoBit assay, Ian Collinson for plasmid pBAD-$_{6H}$11S for purification of 11S, José Penadés and Ross Fitzgerald for *S. aureus* strain JP5347, and Sharon Peacock for strain EMRSA15.

Data, code and materials

The datasets supporting this article have been uploaded to FigShare (https://doi.org/10.6084/m9.figshare.25368598).

485   **Table 1**. *S. aureus* strains used in this study

Strain	Description	Reference
COL	MRSA, *agr, essC-1* variant strain	[45, 46]
COLΔ*essC*	COL with markerless deletion of *essC*	[22]
RN6390	NCTC8325 derivative. *rbsU, tcaR,* cured of φ11, φ12, φ13. *essC-1* variant strain	[47, 48]
RN6390Δ*essC*	RN6390 with markerless deletion of *essC*	[8]
JP5347	Human isolate, *essC-1* variant strain	This work
JP5347Δ*essC*	JP5347 with markerless deletion of *essC*	This work
MRSA252	Nosocomial HA-MRSA isolate, representative of Epidemic MRSA-16. *essC-2* variant strain	[49]
MRSA252Δ*essC*	MRSA252 with markerless deletion of *essC*	This work
10.1252.X	Livestock-associated ST398 isolate. *essC-3* variant strain	[33]
10.1252.XΔ*essC*	10.1252.X with markerless deletion of *essC*	This work
EMRSA15	EMRSA-15 clonal complex 22 human isolate. *essC-4* variant strain.	[50]
EMRSA15Δ*essC*	EMRSA15 with markerless deletion of *essC*	This work
COL$_{esxA-pep86}$	Pep86 coding sequence (VSGWRLFKKIS) fused to the 3' end of *esxA* in COL	This work
COLΔ*essC*$_{esxA-pep86}$	Pep86 coding sequence (VSGWRLFKKIS) fused to the 3' end of *esxA* in COLΔ*essC*	This work

Table 2. Plasmids used in this study

Plasmid	Details	Ref/source
pRab11	*E. coli/S. aureus* shuttle vector, carries $P_{xyl/tet}$ for inducible expression. Amp^r, cml^r.	[51]
pRab11-esxApep86	For ATC-inducible expression of EsxA with a C-terminal pep86 tag (VSGWRLFKKIS)	This study
pRab11-pep86trxA	For ATC-inducible expression of TrxA with a N-terminal pep86 tag (MVSGWRLFKKIS)	This study
pRab11-CBED-DG	Plasmid for overproduction of the *essC-1* substrate EsaD with a C-terminal HA tag, along with its immunity protein EsaG and secretion factors EsxB, EsxC, EsxD and EsaE.	[24]
pRab11-tspA$_{1-328}$-pep86_2603_2602_2601	For ATC-inducible production of TspA$_{NT}$ with a C-terminal pep86 tag (VSGWRLFKKIS), along with LapT1 (SACOL2603), LapT2 (SACOL2602) and SACOL2601.	This work
pRab11-tspA$_{1-328}$-pep86_2602-2601	For ATC-inducible production of TspA$_{NT}$ with a C-terminal pep86 tag (VSGWRLFKKIS), along with LapT2 (SACOL2602) and SACOL2601.	This work
pRab11-tspA$_{1-328}$-pep86_2603_2601	For ATC-inducible production of TspA$_{NT}$ with a C-terminal pep86 tag (VSGWRLFKKIS), along with LapT1 (SACOL2603) and SACOL2601.	This work
pRab11-tspA$_{1-328}$-pep86_2603-2602	For ATC-inducible production of TspA$_{NT}$ with a C-terminal pep86 tag (VSGWRLFKKIS), along with LapT1 (SACOL2603) and LapT2 (SACOL2602).	This work
pIMAY	*E. coli/S. aureus* shuttle vector, temperature sensitive, cml^r.	[29]
pIMAYessC	pIMAY carrying the flanking regions of *essC-1*	[8]
pIMAYessC-MRSA252	pIMAY carrying the flanking regions of *essC-2*	This work
pIMAYessC-ST398	pIMAY carrying the flanking regions of *essC-3*	This work
pIMAYessC-EMRSA15	pIMAY carrying the flanking regions of *essC-4*	This work
pIMAY-Z	*E. coli/S. aureus* shuttle vector, temperature sensitive, cml^r.	[30]
pIMAY-Z_esxApep86	pIMAY-Z carrying *esxA-pep86* and chromosomal flanking regions.	This work
pBAD-$_{6H}$11S	Expression vector for purification of 11S	[28]
pQE70	*E. coli* expression vector	Qiagen

pQE70-$_{Tstrep}$SACOL2603$_{myc}$-2602-2601$_{HA-his}$TspA	For production of TspA with an N-terminal his tag, alongside LapT1 with an N-terminal twinstrep tag, LapT2 with an N-terminal myc tag and SACOL2601 with a C-terminal HA tag	This work

    Figure legends

Figure 1. The NanoBit T7-secretion assay

A. Schematic representation of the NanoBit secretion assay. The T7SSb substrate EsxA with a

C-terminal pep86 tag is produced in the *S. aureus* cytoplasm, and 11S and furimazine (the

NanoLuc large subunit and substrate) are provided outside the cell. Secretion of EsxA-pep86

via the T7SS results in functional complementation of 11S, which luminesces in the presence

of furimazine and O_2. Note that the cartoon is not an accurate representation of the

stoichiometry and architecture of the T7SSb, which are unknown.

B, D. COL wild-type or Δ*essC* strains carrying the indicated plasmids were grown in 5 ml

cultures. At OD_{600} = 0.5 ATC was added to induce gene expression from pRab11. When cells

reached OD_{600} = 2, samples corresponding to the whole cell culture, the clarified culture

medium ('supernatant') and lysed cells ('cytoplasm') were prepared. Serial two-fold dilutions

of whole cell cultures, clarified supernatant and cytoplasmic fractions were prepared, and 11S

and furimazine were added to each. The data presented correspond to the mean

luminescence readings of five biological replicates and error bars represent the SEM. Two-

way ANOVA was performed to determine statistical significance (ns $p>0.05$; **** $p<0.0001$).

C, E. Lysed whole cell (wc) and clarified culture supernatant (sn) fractions from (B) and (D)

were analysed by immunoblot with antibodies against EsxA (top) or TrxA (bottom).

Supernatant samples were concentrated by TCA precipitation prior to analysis, and the

amount analysed corresponds to 6 x more culture volume than for lysed cell samples.

Figure 2. High throughput secretion analysis of strains producing chromosomally-encoded

EsxA-pep86.

A. The indicated strains were grown in 5 ml cultures and ATC was added at OD_{600} = 0.5 to

induce gene expression from pRab11. 'pEsaD-HA' denotes plasmid pRab11-CBED-DEG,

carrying an HA-tagged copy of the T7 substrate EsaD, along with its accessory secretion

factors [24]. At OD_{600} = 2, lysed whole cell (wc) and clarified culture supernatant (sn) fractions were

prepared and analysed by immunoblot with antibodies against the HA tag (to detect EsaD-

HA), EsxA or TrxA. Supernatant samples were concentrated by TCA precipitation prior to

analysis, and the amount analysed corresponds to 6 x more culture volume than for lysed cell

samples.

B. Growth curve for cultures of COL wild-type and Δ*essC* strains, each producing chromosomally encoded ExsA with a C-terminal pep86 tag from the native locus. 192 replicate 50 μl cultures (64 technical replicates x 3 biological replicates) were grown in 384-well plates at 37°C. Furimazine and 11S were added at 360 min (dotted line). Mean OD_{600} values are plotted and error bars correspond to the SEM (n=3).

C. Luminescence readings at ten minute intervals for the cultures in (B) following initiation of luminescence with furimazine and 11S at 360 minutes. Error bars correspond to the SEM (n=3).

D. A single overnight culture of each COL*esxA-pep86* and COLΔ*essC*esxA-pep86* was diluted to an OD_{600} of 0.1 and used to inoculate 64 individual wells of a 384 well plate. After 360 minutes growth, furimazine and 11S were added and a single luminescence reading from each well was taken at 430 minutes.

E. As for (D) except that three overnight cultures of each COL*esxA-pep86* and COL Δ*essC*esxA-pep86* were used, giving 192 individual data points for each strain. Statistical significance in (D) and (E) were assessed with the Mann-Whitney test, with **** indicating p< 0.0001 for each case.

Figure 3. ExsA secretion in different S. aureus strains and at different temperatures

A. Wild-type and Δ*essC* variants of the indicated strains were transformed with pRab11-esxApep86 and cultured in 384-well plates at 37°C. Expression of *esxA-pep86* was induced by addition of ATC at 180 minutes, and luminescence was initiated by addition of furimazine and 11S at 220 minutes. Luminescence readings taken at ten minute intervals (shown in Fig. S1B) were divided by OD_{600} readings to give the relative luminescence. The values for Δ*essC* relative luminescence were subtracted from those of the wild-type relative luminescence to give a relative secretion value for each time point. For each strain pair the time point with the peak value for relative secretion is presented. Data represent the mean of three biological replicates each with 16 technical replicates. Error bars correspond to the SEM (n=3).

B. Secretion assays were performed as in (A), but each strain pair was cultured at 30°C, 34°C and 37°C (data for 37°C is reproduced from (A) for the sake of comparison). The timings of ATC induction and luminescence initiation were adjusted for the slower growth rates at 30°C and 34°C (see Fig S2A and methods) and raw luminescence readings are shown in Figure S2B.

Figure 4. Identification of TspA secretion factors

A. Locus diagrams depicting the genetic neighbourhood of *tspA* (*SACOL0643*, red – top) and the T7SS-associated genes *SACOL2603*, *SACOL2602* and *SACOL2601* (orange, yellow and blue – middle) in strain COL. Bottom – the *SACOL2603* equivalent locus in strain SID53 has a *tspA2-tsaI2* insertion between the homologues of *SACOL2602* and *SACOL2601*. *SACOL2603* encodes a DUF3130/TIGR04917 family protein.

B. COL wild-type or Δ*essC* strains carrying plasmid pRab11-tspA1-328-pep86_2603_2602_2601 were grown in 5 ml cultures at 37°C. At OD_{600} = 0.5 ATC was added to induce gene expression from pRab11. When cells reached OD_{600} = 2, samples corresponding to the whole cell culture ('WC') and the clarified culture medium ('SP') were prepared and 11S and furimazine were added to each. The data presented correspond to the mean luminescence readings of three biological replicates and error bars represent the SEM. Statistical significance for whole cell culture of the wild-type vs clarified culture medium was assessed with the Mann-Whitney test, with *** indicating p< 0.001. There was no significant difference between values for the whole cell vs clarified culture medium for the Δ*essC* strain.

C. Wild-type and Δ*essC* variants of strain RN6390 were transformed with the indicated plasmids and cultured in 384-well plates at 34°C. Expression from pRab11 was induced by addition of ATC at 120 minutes, and luminescence was initiated by addition of furimazine and 11S at 260 minutes. Luminescence readings were taken at the 280 minute timepoint and were divided by OD_{600} readings to give the relative luminescence. Data represent the mean of five biological replicates each with 16 technical replicates. Error bars correspond to the SEM (n=5). The relative luminescence of RN6390 harbouring each plasmid containing the indicated individual gene deletion was compared with the relative luminescence signal of RN6390 harbouring pRab11-tspA$_{1-328}$-pep86_2603-2602-2601 using the Mann-Whitney test, * p< 0.05; ** p<0.01.

D. *E. coli* M15 cells carrying pQE70-$_{Tstrep}$SACOL2603$_{myc}$-2602-2601$_{HA-his}$TspA were grown in LB medium. Following induction of gene expression with IPTG, complexes were purified by streptactin- affinity purification, and the resulting sample was analysed by size-exclusion chromatography (SEC).

E. Fractions from within the dotted lines in (D) were subject to SDS-PAGE and analysed by coomassie staining (left panel) or by western blotting with antibodies against the tags on each component (right panel).

References

1. Turner, NA, Sharma-Kuinkel, BK, Maskarinec, SA, Eichenberger, EM, Shah, PP, Carugati, M, Holland, TL, Fowler, VG, Jr. 2019 Methicillin-resistant *Staphylococcus aureus*: an overview of basic and clinical research. *Nat Rev Microbiol*. **17**, 203-218. (10.1038/s41579-018-0147-4)

2. Shariati, A, Dadashi, M, Moghadam, MT, van Belkum, A, Yaslianifard, S, Darban-Sarokhalil, D. 2020 Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate *Staphylococcus aureus* clinical isolates: a systematic review and meta-analysis. *Sci Rep*. **10**, 12689. (10.1038/s41598-020-69058-z)

3. Boardman, ER, Palmer, T, Alcock, F. 2023 Interbacterial competition mediated by the type VIIb secretion system. *Microbiology*. **169**, (10.1099/mic.0.001420)

4. Bowman, L, Palmer, T. 2021 The type VII secretion system of *Staphylococcus. Annu Rev Microbiol*. **75**, 471-494. (10.1146/annurev-micro-012721-123600)

5. Burts, ML, DeDent, AC, Missiakas, DM. 2008 EsaC substrate for the ESAT-6 secretion pathway and its role in persistent infections of S*taphylococcus aureus*. *Mol Microbiol*. **69**, 736-746. (DOI 10.1111/j.1365-2958.2008.06324.x)

6. Burts, ML, Williams, WA, DeBord, K, Missiakas, DM. 2005 EsxA and EsxB are secreted by an ESAT-6-like system that is required for the pathogenesis of *Staphylococcus aureus* infections. *Proc Natl Acad Sci U S A*. **102**, 1169-1174.

7. Ishii, K, Adachi, T, Yasukawa, J, Suzuki, Y, Hamamoto, H, Sekimizu, K. 2014 Induction of virulence gene expression in *Staphylococcus aureus* by pulmonary surfactant. *Infect Immun*. **82**, 1500-1510. (10.1128/IAI.01635-13)

8. Kneuper, H, Cao, ZP, Twomey, KB, Zoltner, M, Jager, F, Cargill, JS, Chalmers, J, van der Kooi-Pol, MM, van Dijl, JM, Ryan, RP*, et al.* 2014 Heterogeneity in *ess* transcriptional organization and variable contribution of the Ess/Type VII protein secretion system to virulence across

closely related *Staphyloccus aureus* strains. *Mol Microbiol*. **93**, 928-943.
(10.1111/mmi.12707)

9. Wang, Y, Hu, M, Liu, Q, Qin, J, Dai, Y, He, L, Li, T, Zheng, B, Zhou, F, Yu, K, *et al.* 2016 Role of
the ESAT-6 secretion system in virulence of the emerging community-associated
Staphylococcus aureus lineage ST398. *Sci Rep*. **6**, 25163. (10.1038/srep25163)

10. Garrett, SR, Higginson, AB, Palmer, T. 2024 Multiple variants of the type VII secretion
system in Gram-positive bacteria. *bioRxiv*. **BIORXIV/2024/577966**
(https://doi.org/10.1101/2024.01.30.577966)

11. Whitney, J.C, Peterson, SB, Kim, J, Pazos, M, Verster, AJ, Radey, MC, Kulasekara, HD, Ching,
MQ, Bullen, NP, Bryant, D, *et al.* 2017 A broadly distributed toxin family mediates contact-
dependent antagonism between gram-positive bacteria. *Elife*. **6**, (10.7554/eLife.26938)

12. Kobayashi, K. 2021 Diverse LXG toxin and antitoxin systems specifically mediate
intraspecies competition in *Bacillus subtilis* biofilms. *PLoS Genet*. **17**, e1009682.
(10.1371/journal.pgen.1009682)

13. Chatterjee, A, Willett, JLE., Dunny, GM, Duerkop, BA 2021 Phage infection and sub-lethal
antibiotic exposure mediate *Enterococcus faecalis* type VII secretion system dependent
inhibition of bystander bacteria. *PLoS Genet*. **17**, e1009204. (10.1371/journal.pgen.1009204)

14. Warne, B, Harkins, CP, Harris, SR, Vatsiou, A, Stanley-Wall, N, Parkhill, J, Peacock, SJ,
Palmer, T, Holden, MT. 2016 The Ess/Type VII secretion system of *Staphylococcus aureus*
shows unexpected genetic diversity. *BMC Genom*. **17**, 222. (10.1186/s12864-016-2426-7)

15. Bunduc, CM, Fahrenkamp, D, Wald, J, Ummels, R, Bitter, W, Houben, ENG., Marlovits, TC.
2021 Structure and dynamics of a mycobacterial type VII secretion system. *Nature*. **593**, 445-
448. (10.1038/s41586-021-03517-z)

16. Beckham, KSH., Ritter, C, Chojnowski, G, Ziemianowicz, DS, Mullapudi, E, Rettel, M,
Savitski, MM, Mortensen, SA, Kosinski, J, Wilmanns, M. 2021 Structure of the mycobacterial
ESX-5 type VII secretion system pore complex. *Sci Adv*. **7**, (10.1126/sciadv.abg9923)

17. Jager, F, Kneuper, H, Palmer, T. 2018 EssC is a specificity determinant for *Staphylococcus*
aureus type VII secretion. *Microbiology*. **164**, 816-820. (10.1099/mic.0.000650)

18. Huppert, L. A., Ramsdell, T. L., Chase, M. R., Sarracino, D. A., Fortune, S. M., Burton, B. M.
2014 The ESX system in *Bacillus subtilis* mediates protein secretion. *PLoS One*. **9**, e96267.
(10.1371/journal.pone.0096267)

19. Anderson, M, Aly, KA, Chen, YH, Missiakas, D. 2013 Secretion of atypical protein substrates
by the ESAT-6 secretion system of *Staphylococcus aureus*. *Mol Microbiol*. **90**, 734-743.
(10.1111/mmi.12395)

20. Renshaw, PS, Lightbody, KL, Veverka, V, Muskett, FW, Kelly, G, Frenkiel, TA, Gordon, SV,
Hewinson, RG, Burke, B, Norman, J, *et al.* 2005 Structure and function of the complex formed
by the tuberculosis virulence factors CFP-10 and ESAT-6. *EMBO J*. **24**, 2491-2498.
(10.1038/sj.emboj.7600732)

21. Pallen, MJ. 2002 The ESAT-6/WXG100 superfamily -- and a new Gram-positive secretion
system? *Trends Microbiol*. **10**, 209-212.

22. Ulhuq, FR, Gomes, MC, Duggan, GM, Guo, M, Mendonca, C, Buchanan, G, Chalmers, JD,
Cao, Z, Kneuper, H, Murdoch, S, *et al.* 2020 A membrane-depolarizing toxin substrate of the
Staphylococcus aureus type VII secretion system mediates intraspecies competition. *Proc Natl*
Acad Sci U S A. **117**, 20836-20847. (10.1073/pnas.2006110117)

23. Garrett, SR, Mietrach, N, Deme, J, Bitzer, A, Yang, Y, Ulhuq, FR, Kretschmer, D, Heilbronner,
S, Smith, TK, Lea, SM, *et al.* 2023 A type VII-secreted lipase toxin with reverse domain
arrangement. *Nat Commun*. **14**, 8438. (10.1038/s41467-023-44221-y)

24. Yang, Y, Boardman, E, Deme, J, Alcock, F, Lea, S, Palmer, T. 2023 Three small partner

proteins facilitate the type VII-dependent secretion of an antibacterial nuclease. *mBio*. **14**,

e0210023. (10.1128/mbio.02100-23)

25. Cao, Z, Casabona, MG, Kneuper, H, Chalmers, JD, Palmer, T. 2016 The type VII secretion

system of *Staphylococcus aureus* secretes a nuclease toxin that targets competitor bacteria.

Nat Microbiol. **2**, 16183. (10.1038/nmicrobiol.2016.183)

26. Klein, TA, Grebenc, DW, Shah, PY, McArthur, OD, Dickson, BH, Surette, MG, Kim, Y,

Whitney, JC. 2022 Dual targeting factors are required for LXG toxin export by the bacterial

type VIIb secretion system. *mBio*. **13**, e0213722. (10.1128/mbio.02137-22)

27. Klein, TA, Shah, PY, Gkragkopoulou, P, Grebenc, DW, Kim, Y, Whitney, JC. 2024 Structure

of a tripartite protein complex that targets toxins to the type VII secretion system. *Proc Natl*

Acad Sci U S A. **121**, e2312455121. (10.1073/pnas.2312455121)

28. Pereira, GC, Allen, WJ, Watkins, DW, Buddrus, L, Noone, D, Liu, X, Richardson, AP,

Chacinska, A, Collinson, I. 2019 A high-resolution luminescent assay for rapid and continuous

monitoring of protein translocation across biological membranes. *J Mol Biol*. **431**, 1689-1699.

(10.1016/j.jmb.2019.03.007)

29. Monk, IR, Shah, IM, Xu, M, Tan, MW, Foster, TJ. 2012 Transforming the untransformable:

application of direct transformation to manipulate genetically *Staphylococcus aureus* and

Staphylococcus epidermidis. *mBio*. **3**, (10.1128/mBio.00277-11)

30. Monk, IR, Stinear, TP. 2021 From cloning to mutant in 5 days: rapid allelic exchange in

Staphylococcus aureus. *Access Microbiol*. **3**, 000193. (10.1099/acmi.0.000193)

31. Miller, M, Donat, S, Rakette, S, Stehle, T, Kouwen, TR, Diks, SH, Dreisbach, A, Reilman, E,

Gronau, K, Becher, D*, et al.* 2010 Staphylococcal PknB as the first prokaryotic representative

of the proline-directed kinases. *PLoS ONE*. **5**, e9057. (10.1371/journal.pone.0009057)

32. Gilchrist, CLM., Chooi, YH. 2021 Clinker & clustermap.js: Automatic generation of gene

cluster comparison figures. *Bioinformatics*. (10.1093/bioinformatics/btab007)

33. Casabona, MG, Kneuper, H, Alferes de Lima, D, Harkins, CP, Zoltner, M, Hjerde, E, Holden,

MTG., Palmer, T. 2017 Haem-iron plays a key role in the regulation of the Ess/type VII

secretion system of *Staphylococcus aureus* RN6390. *Microbiology*. **163**, 1839-1850.

(10.1099/mic.0.000579)

34. England, CG, Ehlerding, EB, Cai, W. 2016 NanoLuc: A small luciferase Is brightening up the

field of bioluminescence. *Bioconjug Chem*. **27**, 1175-1187.

(10.1021/acs.bioconjchem.6b00112)

35. Allen, WJ, Watkins, DW, Dillingham, MS, Collinson, I. 2020 Refined measurement of SecA-

driven protein secretion reveals that translocation is indirectly coupled to ATP turnover. *Proc*

Natl Acad Sci U S A. **117**, 31808-31816. (10.1073/pnas.2010906117)

36. Zhou, WJ, Hao, BH, Bricker, TM, Theg, SM. 2023 A real-time analysis of protein transport

via the twin arginine translocation pathway in response to different components of the

protonmotive force. *J Biol Chem*. **299**, (ARTN 105286 10.1016/j.jbc.2023.105286)

37. Spencer, BL, Job, AM, Robertson, CM, Hameed, ZA, Serchejian, C, Wiafe-Kwakye, CS,

Mendonça, JC, Apolonio, MA, Nagao, PE, Neely, MN*, et al.* 2023 Heterogeneity of the group

B streptococcal type VII secretion system and influence on colonization of the female genital

tract. *Mol Microbiol*. **120**, 258-275. (10.1111/mmi.15115)

38. Kenny, JG, Ward, D, Josefsson, E, Jonsson, IM, Hinds, J, Rees, HH, Lindsay, JA, Tarkowski,

A, Horsburgh, MJ. 2009 The response to unsaturated long chain free fatty acids: Survival

mechanisms and virulence implications. *Plos One*. **4**, (ARTN e4344

10.1371/journal.pone.0004344)

39. Lopez, MS, Tan, IS, Yan, D., Kang, J, McCreary, M, Modrusan, Z, Austin, CD, Xu, M, Brown,

EJ. 2017 Host-derived fatty acids activate type VII secretion in *Staphylococcus aureus. Proc*

Natl Acad Sci U S A. **114**, 11223-11228. (10.1073/pnas.1700627114)

40. Bischoff, M, Entenza, JM, Giachino, P. 2001 Influence of a functional *sigB* operon on the

global regulators *sar* and *agr* in *Staphylococcus aureus*. *J Bacteriol*. **183**, 5171-5179.

(10.1128/jb.183.17.5171-5179.2001)

41. Crosby, HA, Tiwari, N, Kwiecinski, JM, Xu, Z., Dykstra, A, Jenul, C, Fuentes, EJ, Horswill, AR.

2020 The *Staphylococcus aureus* ArlRS two-component system regulates virulence factor

expression through MgrA. *Mol Microbiol*. **113**, 103-122. (10.1111/mmi.14404)

42. Dunman, PM, Murphy, E, Haney, S, Palacios, D, Tucker-Kellogg, G, Wu, S, Brown, EL,

Zagursky, RJ, Shlaes, D, Projan, SJ. 2001 Transcription profiling-based identification of

Staphylococcus aureus genes regulated by the *agr* and/or *sarA* loci. *J Bacteriol*. **183**, 7341-

7353. (10.1128/JB.183.24.7341-7353.2001)

43. Schulthess, B, Bloes, DA, Berger-Bachi, B. 2012 Opposing roles of sigmaB and sigmaB-

controlled SpoVG in the global regulation of *esxA* in *Staphylococcus aureus*. *BMC Microbiol*.

12, 17. (10.1186/1471-2180-12-17)

44. Casabona, MG, Buchanan, G, Zoltner, M, Harkins, CP, Holden, MTG., Palmer, T. 2017

Functional analysis of the EsaB component of the *Staphylococcus aureus* Type VII secretion

system. *Microbiology*. **163,** 1851-1863. (10.1099/mic.0.000580)

45. Dyke, KG, Jevons, MP, Parker, MT. 1966 Penicillinase production and intrinsic resistance

to penicillins in *Staphylococcus aures*. *Lancet*. **1**, 835-838.

46. Gill, SR, Fouts, DE, Archer, GL, Mongodin, EF, Deboy, RT, Ravel J, Paulsen, IT, Kolonay, JF,

Brinkac, L, Beanan, M*, et al.* 2005 Insights on evolution of virulence and resistance from the

complete genome analysis of an early methicillin-resistant *Staphylococcus aureus* strain and

a biofilm-producing methicillin-resistant *Staphylococcus epidermidis* strain. *J Bacteriol*. **187**,

2426-2438. (10.1128/JB.187.7.2426-2438.2005)

47. Novick, RP, Ross, HF, Projan, SJ, Kornblum, J, Kreiswirth, B, Moghazeh, S. 1993 Synthesis

of staphylococcal virulence factors is controlled by a regulatory RNA molecule. *EMBO J*. **12**,

3967-3975.

48. Garrett, SR, Mariano, G, Palmer, T. 2022 Genomic analysis of the progenitor strains of

Staphylococcus aureus RN6390. *Access Microbiology*. **4,** 11.

49. Holden, MT, Feil, EJ, Lindsay, JA, Peacock, SJ, Day, NP, Enright, MC, Foster, TJ, Moore, CE,

Hurst, L, Atkin, R*, et al.* 2004 Complete genomes of two clinical *Staphylococcus aureus* strains:

evidence for the rapid evolution of virulence and drug resistance. *Proc Natl Acad Sci U S A*.

101, 9786-9791. (10.1073/pnas.0402521101)

50. Donker, T, Reuter, S, Scriberras, J, Reynolds, R, Brown, NM, Torok, ME, James, R, Network,

E, Aanensen, DM, Bentley, SD*, et al.* 2017 Population genetic structuring of methicillin-

resistant *Staphylococcus aureus clone* EMRSA-15 within UK reflects patient referral patterns.

Microb Genom. **3**, e000113. (10.1099/mgen.0.000113)

51. Helle, L, Kull, M, Mayer, S, Marincola, G, Zelder, ME, Goerke, C, Wolz, C, Bertram, R. 2011

Vectors for improved Tet repressor-dependent gradual gene induction or silencing in

Staphylococcus aureus. *Microbiology*. **157**, 3314-3323. (10.1099/mic.0.052548-0)

1A

1B

1C

		pRab11	pRab11-esxApep86		

1D

1E

		pRab11	pRab11-pep86trxA		

3A

3B

4A

4B

4C

4D

4E

Coomassie

Western blot